Johnson & Johnson (UKEX:JNJ) Cyclically Adjusted Revenue per Share: ₴900.59 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:JNJ Johnson & Johnson UKEX:JNJ
85 GF Score
Price ₴5,947.00
GF Value ₴4,398.67
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Cyclically Adjusted Revenue per Share?

Johnson & Johnson UKEX:JNJ 85 Cyclically Adjusted Revenue per Share is ₴900.59 as of Jun. 2026. GuruFocus rates UKEX:JNJ with a GF Score™ of 85/100 and a GF Value™ of ₴4,398.67. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Johnson & Johnson's adjusted revenue per share for the three months ended in Jun. 2026 was ₴463.423. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₴900.59 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Johnson & Johnson's average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Johnson & Johnson was 10.10% per year. The lowest was 3.30% per year. And the median was 7.10% per year.

As of today (2026-08-12), Johnson & Johnson's current stock price is ₴5947.00. Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₴900.59. Johnson & Johnson's Cyclically Adjusted PS Ratio of today is 6.60.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Johnson & Johnson was 6.85. The lowest was 3.98. And the median was 5.05.


Johnson & Johnson  (UKEX:JNJ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Johnson & Johnson's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5947.00/900.59
=6.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Johnson & Johnson was 6.85. The lowest was 3.98. And the median was 5.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Johnson & Johnson Cyclically Adjusted Revenue per Share Related Terms


Johnson & Johnson Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Cyclically Adjusted Revenue per Share Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1,180.59 1,306.72 1,465.98 1,065.83

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,426.11 1,187.99 1,065.83 922.32 900.59

UKEX:JNJ vs ABBV, MRK, LLY: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PS Ratio falls into.


UKEX:JNJ
85GF Score
Johnson & Johnson UKEX:JNJ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Johnson & Johnson's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=463.423/333.9520*333.9520
=463.423

Current CPI (Jun. 2026) = 333.9520.

Johnson & Johnson Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 285.834 241.428 395.376
201612 292.479 241.432 404.561
201703 288.164 243.801 394.719
201706 307.017 244.955 418.562
201709 320.679 246.819 433.886
201712 329.056 246.524 445.753
201803 327.231 249.554 437.899
201806 341.984 251.989 453.219
201809 333.299 252.439 440.922
201812 334.249 251.233 444.301
201903 331.443 254.202 435.426
201906 341.297 256.143 444.973
201909 346.878 256.759 451.165
201912 346.789 256.974 450.672
202003 346.099 258.115 447.787
202006 307.340 257.797 398.130
202009 352.864 260.280 452.742
202012 376.025 260.474 482.099
202103 373.127 264.877 470.432
202106 389.853 271.696 479.183
202109 389.807 274.310 474.561
202112 163.333 278.802 195.642
202203 392.509 287.504 455.921
202206 402.251 296.311 453.350
202209 335.693 296.808 377.703
202212 335.771 296.797 377.805
202303 358.281 301.836 396.403
202306 366.159 305.109 400.773
202309 374.130 307.789 405.932
202312 393.142 306.746 428.011
202403 393.131 312.332 420.344
202406 414.073 314.175 440.138
202409 413.509 315.301 437.969
202412 414.206 315.605 438.285
202503 403.554 319.799 421.414
202506 438.505 322.561 453.990
202509 441.389 324.800 453.826
202512 449.193 324.054 462.913
202603 439.654 330.213 444.632
202606 463.423 333.952 463.423

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₴900.59 mean?
Johnson & Johnson (UKEX:JNJ) has a Cyclically Adjusted Revenue per Share of ₴900.59 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Johnson & Johnson and its competitors.
Is Johnson & Johnson's Cyclically Adjusted Revenue per Share too high?
Johnson & Johnson's current Cyclically Adjusted Revenue per Share is ₴900.59. Overall, Johnson & Johnson has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Cyclically Adjusted Revenue per Share compare to ABBV and MRK?
Johnson & Johnson's Cyclically Adjusted Revenue per Share of ₴900.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current Cyclically Adjusted Revenue per Share is ₴900.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Johnson & Johnson (UKEX:JNJ) has a current Cyclically Adjusted Revenue per Share of ₴900.59. The stock's GF Value™ is ₴4,398.67, compared to a current price of ₴5,947.00 — trading 35.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₴900.59. Johnson & Johnson's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Johnson & Johnson (UKEX:JNJ), the current Cyclically Adjusted Revenue per Share is ₴900.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (UKEX:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of ₴5,947.00 is trading 35.2% above its estimated GF Value™ of ₴4,398.67.

Key valuation signals for UKEX:JNJ:

  • Cyclically Adjusted Revenue per Share: ₴900.59
  • GF Value™: ₴4,398.67 vs. price of ₴5,947.00 (35.2% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the UKEX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
85GF Score

Get the complete analysis for UKEX:JNJ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴5,947.00
Price
₴4,398.67
GF Value